Ownership and insider activity for Evaxion Biotech A/S (EVAX): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases.
Price
| Price | $3.03 |
| Market Cap | $19M |
| Exchange | NASDAQ |
| Country | DK |
Balance Sheet (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $468000 | $7.4M | $9.6M | $5.8M | $32.2M | $13.2M | $5.6M | $5.1M | $23.2M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | $2.1M | $772000 | 0 | 0 | 0 | 0 | 0 | $1.9M | $1.1M |
| Inventory | 0 | -$1.4M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $2.7M | $8.4M | $11.0M | $10.9M | $34.7M | $17.0M | $8.3M | $8.8M | $24.9M |
| Property, Plant & Equipment | $213000 | $130000 | $101000 | $221000 | $5.2M | $4.7M | $4.3M | $3.5M | $3.3M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | $100000 | $93000 | 0 | 0 | 0 | 0 |
| Total Assets | $2.9M | $8.5M | $11.1M | $12.0M | $40.2M | $22.0M | $12.9M | $12.5M | $28.4M |
| Accounts Payable | $59000 | $139000 | $646000 | $3.7M | $2.8M | $2.1M | $2.7M | $3.0M | $2.2M |
| Short-term Debt | 0 | $8.6M | 0 | 0 | $126000 | $136000 | $159000 | $159000 | $190000 |
| Total Current Liabilities | $303000 | $9.4M | $1.7M | $4.9M | $4.3M | $3.8M | $7.1M | $4.4M | $4.3M |
| Long-term Debt | 0 | 0 | 0 | 0 | $1.0M | $7.9M | $8.5M | $8.0M | $5.3M |
| Total Liabilities | $399000 | $9.4M | $1.7M | $4.9M | $7.7M | $13.7M | $17.6M | $14.1M | $11.4M |
| Retained Earnings | -$3.5M | -$7.0M | -$15.8M | -$27.3M | -$50.4M | -$85.8M | -$108.0M | -$118.5M | -$126.2M |
| Total Equity | $2.5M | -$931000 | $9.4M | $7.0M | $32.4M | $8.3M | -$4.7M | -$1.7M | $17.0M |
| Total Debt | $162000 | $8.7M | $36000 | $20000 | $3.7M | $10.3M | $10.9M | $10.1M | $7.5M |
| Net Debt | -$306000 | $1.2M | -$9.5M | -$5.8M | -$28.5M | -$2.9M | $5.3M | $5.0M | -$15.7M |
| Working Capital | $2.4M | -$1.0M | $9.2M | $6.0M | $30.4M | $13.2M | $1.3M | $4.4M | $20.6M |
Financial Health
| Debt / Equity | 0.75 |
| Current Ratio | 5.06 |
| Piotroski F-Score | 5 |
| Altman Z-Score | -4.54 |
Profitability
| Return on Equity | -45.23% |
| Return on Invested Capital | -33.44% |
| Return on Assets | -27.13% |
| Gross Margin | 100.00% |
| Operating Margin | -115.98% |
| Net Margin | -115.49% |
Related companies: ANVS · BCAB · BTAI · CELU · GBIO · MURA · PYPD
Explore sector: Healthcare · Biotechnology
More sections of EVAX: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks